Researchers have identified a common signature of how psychedelic drugs alter the brain. A landmark international study reveals that five different substances produce a remarkably similar pattern of disruption to normal brain activity.
The findings, published in Nature Medicine in April 2026, draw on more than 500 brain scans from 267 participants across five countries. This is the most comprehensive analysis to date of psychedelic drugs and the brain. Scientists pooled data from 11 independent studies examining psilocybin, LSD, DMT, mescaline and ayahuasca. They applied a uniform analytical framework to cut through years of fragmented and sometimes contradictory research.
How Psychedelic Drugs and the Brain’s Hierarchy Collide
The most striking discovery was that all five substances appear to “flatten” the brain’s natural processing hierarchy. Under normal circumstances, the brain operates along a clear gradient. Higher-order networks handle abstract thought and self-reflection. More primitive networks handle vision and basic sensation. These systems communicate in an organised, structured way.
Under the influence of psychedelics, that structure breaks down.
“All five drugs dissolve the common order, the usual hierarchy of brain systems,” said Dr Danilo Bzdok, a senior author on the study from McGill University in Montreal. “They flatten the hierarchy and that probably underlies what some people describe as this raw access to one’s own consciousness.”
The study found a sharp increase in communication between the brain’s transmodal networks and unimodal networks. Transmodal networks handle high-level thinking, including the default mode and frontoparietal networks. Unimodal networks handle vision and physical sensation. Put simply, parts of the brain that rarely talk to one another begin talking at once.
“You have an unleashed cross-talk between brain systems,” Dr Bzdok said. “They are wildly communicating with each other.”
What the Scans Revealed About Psychedelics and Brain Function
The research team, known as the BOLD Psychedelic Consortium, used resting-state functional MRI (fMRI) to measure spontaneous brain activity. They scanned participants while each substance was active. The team reprocessed all datasets through a single pipeline. They then applied a Bayesian statistical framework to measure not just whether effects existed, but how confident the findings were.
Increases in between-network connectivity were the most consistent result across all five drugs. The strongest links appeared between the default mode network and visual or sensorimotor networks.
Deeper brain structures also changed. The caudate and putamen, two striatal regions involved in habit formation, learning and movement, showed increased coupling with sensory and motor areas of the cortex. The researchers suggest this may reflect a disruption to how the brain normally filters sensory input into behaviour.
The role of the thalamus was less clear. Average brain scans suggested thalamic involvement, but the Bayesian modelling found the evidence too weak and inconsistent to support firm conclusions.
Challenging an Earlier Assumption About Psychedelic Brain Effects
One of the most consequential findings was what the study did not confirm. Several earlier papers claimed that psychedelic drugs cause widespread “disintegration” within individual brain networks. The new mega-analysis found little reliable evidence for this.
“Our results challenge previous claims of widespread within-network disintegration,” the authors wrote. Bayesian modelling showed only weak-to-moderate and selective reductions in within-network connectivity. Variability was considerable across substances and brain regions. Many apparent effects from earlier, smaller studies did not hold up under more rigorous scrutiny.
This matters because understanding psychedelics and brain function accurately is essential. It shapes how researchers and clinicians interpret what these substances actually do to a person, both immediately and over time.
Similarities and Differences Between Substances
While a shared neural fingerprint was evident, the drugs were not identical in their effects.
LSD and psilocybin produced the most similar brain changes of all five substances. This aligns with their comparable pharmacological profiles. Both work primarily by activating the 5-HT2A serotonin receptor, which sits in high concentrations in the very brain regions showing the greatest disruption.
DMT produced the most intense pattern of network disruption. However, the DMT dataset included only 16 participants, which limits firm conclusions. Ayahuasca contains DMT alongside monoamine oxidase inhibitors that alter how the body processes it. It showed the most unusual connectivity pattern of all, partly because of its distinct pharmacology and a very small sample size of just nine participants.
Mescaline fell broadly in line with psilocybin and LSD, though with a somewhat more selective pattern of effects.
Why This Study Matters
The research grew out of a widely recognised problem in this field. Despite rapid growth, psychedelic neuroscience had accumulated a confusing and contradictory body of evidence. Different laboratories used different methods with small volunteer groups and reached different conclusions.
“This field is emerging, and it is very important, but they are on shaky ground,” Dr Bzdok said. “We started the study with the ambition to provide a solid foundation.”
Dr Emmanuel Stamatakis, a senior co-author from the University of Cambridge, said the scale of coordination was itself significant. “If psychedelic research is to mature responsibly, it needs large-scale, coordinated evidence.”
The findings carry implications for clinical trials currently exploring these substances as treatments for depression, PTSD and end-of-life anxiety. A search of the clinicaltrials.gov database returns more than 400 active trials involving classic psychedelic compounds. Understanding what these drugs do to the brain is essential before any therapy can be responsibly rolled out at scale.
A Clearer Picture, With Caveats
The authors acknowledge their work has limitations. Scanner types, dosages, routes of administration and scan timing all varied across the 11 included datasets. One dataset had no placebo control group. The strong psychological effects of these substances also make true double-blind conditions very difficult to maintain.
Sample sizes varied significantly by drug. Psilocybin and LSD datasets included 106 and 119 participants respectively. DMT and ayahuasca each contributed fewer than 20. The researchers note this affects how confidently drug-specific conclusions can be drawn.
Head movement is a known problem in fMRI research. Participants under the influence of psychedelics tend to move more than usual. The team removed high-motion scans from the analysis, though some residual effects remain possible.
Taken together, the study paints a consistent picture of psychedelic drugs and the brain. Regardless of their chemical differences, these five substances temporarily reorganise large-scale brain function in a shared and identifiable way. The brain’s normal network order is suspended. Understanding exactly what that means for the people who experience it remains one of the more pressing questions in contemporary neuroscience.
The study, “An international mega-analysis of psychedelic drug effects on brain circuit function,” was published in Nature Medicine on 6 April 2026.
(Source: WRD NEWS)